Introduction: Gastric cancer remains one of the leading causes of mortality from malignant neoplasms in developing countries. The analysis of clinicopathological factors associated with patient survival can contribute to more effective management strategies. Objectives: To evaluate overall survival and prognostic factors in patients with gastric cancer treated at the João de Barros Barreto University Hospital (HUJBB) in Belém, Pará, Brazil. Methods: This retrospective study was based on the analysis of medical records of patients diagnosed with gastric cancer between 2016 and 2023. The study was approved by the Research Ethics Committee of UFPA (CAAE: 96154518.8.0000.5634). All participants signed the Informed Consent Form (ICF). Survival analyses included 70 patients; however, some variables (such as TNM staging, histological type, and tumor location) had missing data and were analyzed proportionally. Clinical data were obtained from the Hospital Management System (AGHU), while sociodemographic information was collected through a semi-structured questionnaire previously completed by the patients. Overall survival was estimated using the Kaplan-Meier method, with group comparisons performed using the log-rank test in R software (version 4.2.1), employing the survival, survminer, and lubridate packages. Results: Of the 70 patients included, 66% were male (n=46) and 34% female (n=24). Patients aged ?60 years represented 49% of the sample. A history of alcohol use was reported by 33 patients, and smoking (current or former) by 36. Intestinal-type adenocarcinoma was identified in 12 cases and diffuse-type in 22. Tumors were located in the cardia in 9 cases and in non-cardia regions in 54. Distant metastases (M1) were found in 5 patients, and advanced lymph node involvement (N1, N2, or N3) in 31. The median overall survival was 35 months (95% CI: 29–41). No statistically significant differences in survival were observed based on age group (<60 vs. ?60 years; p=0.077), alcohol use (p=0.69), smoking status (p=0.72), histological type (intestinal vs. diffuse; p=0.14), T stage (T1–T2 vs. T3–T4; p=0.45), or tumor location (cardia vs. non-cardia; p=0.65). However, significant associations were found for lymph node status (N0 vs. N+; p=0.047) and presence of metastases (M0 vs. M1; p=0.0007), both linked to worse survival outcomes. Among deceased patients, the median time between diagnosis and death was 11 months (range: 0–63 months), with a mean of 15.9 months. This calculation was performed using the lubridate package to determine the interval between dates in months. Conclusions: Lymph node involvement and the presence of distant metastases had a negative impact on overall survival in patients with gastric cancer. These findings highlight the importance of early diagnosis and accurate staging to guide cancer treatment. Study limitations include the small sample size and the retrospective nature of data collection, which may limit the generalizability of the results. Furthermore, the incompleteness of clinicopathological data points to deficiencies in electronic health records, underscoring the need for improvements in hospital documentation systems.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
